Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 20

1.

Cutaneous Immune Cell-Microbiota Interactions Are Controlled by Epidermal JunB/AP-1.

Uluçkan Ö, Jiménez M, Roediger B, Schnabl J, Díez-Córdova LT, Troulé K, Weninger W, Wagner EF.

Cell Rep. 2019 Oct 22;29(4):844-859.e3. doi: 10.1016/j.celrep.2019.09.042.

2.

Mouse Models of Melanoma Bone Metastasis.

Uluçkan Ö.

Methods Mol Biol. 2019;1914:343-348. doi: 10.1007/978-1-4939-8997-3_19.

PMID:
30729475
3.

Fra-2 Expression in Osteoblasts Regulates Systemic Inflammation and Lung Injury through Osteopontin.

Luo Y, Grötsch B, Hannemann N, Jimenez M, Ipseiz N, Uluckan O, Lin N, Schett G, Wagner EF, Bozec A.

Mol Cell Biol. 2018 Oct 29;38(22). pii: e00022-18. doi: 10.1128/MCB.00022-18. Print 2018 Nov 15.

4.

Somatic genome editing with the RCAS-TVA-CRISPR-Cas9 system for precision tumor modeling.

Oldrini B, Curiel-García Á, Marques C, Matia V, Uluçkan Ö, Graña-Castro O, Torres-Ruiz R, Rodriguez-Perales S, Huse JT, Squatrito M.

Nat Commun. 2018 Apr 13;9(1):1466. doi: 10.1038/s41467-018-03731-w.

5.

Chronic systemic inflammation originating from epithelial tissues.

Uluçkan Ö, Wagner EF.

FEBS J. 2017 Feb;284(4):505-516. doi: 10.1111/febs.13904. Epub 2016 Oct 5. Review.

6.

Role of IL-17A signalling in psoriasis and associated bone loss.

Uluçkan Ö, Wagner EF.

Clin Exp Rheumatol. 2016 Jul-Aug;34(4 Suppl 98):17-20. Epub 2016 Jul 20. Review.

7.

Chronic skin inflammation leads to bone loss by IL-17-mediated inhibition of Wnt signaling in osteoblasts.

Uluçkan Ö, Jimenez M, Karbach S, Jeschke A, Graña O, Keller J, Busse B, Croxford AL, Finzel S, Koenders M, van den Berg W, Schinke T, Amling M, Waisman A, Schett G, Wagner EF.

Sci Transl Med. 2016 Mar 16;8(330):330ra37. doi: 10.1126/scitranslmed.aad8996. Epub 2016 Mar 16.

PMID:
27089206
8.

Signalling in inflammatory skin disease by AP-1 (Fos/Jun).

Uluçkan Ö, Guinea-Viniegra J, Jimenez M, Wagner EF.

Clin Exp Rheumatol. 2015 Jul-Aug;33(4 Suppl 92):S44-9. Epub 2015 Oct 12. Review.

PMID:
26458100
9.

Preclinical mouse models of osteosarcoma.

Uluçkan Ö, Segaliny A, Botter S, Santiago JM, Mutsaers AJ.

Bonekey Rep. 2015 May 6;4:670. doi: 10.1038/bonekey.2015.37. eCollection 2015.

10.

Characterization of mouse model-derived osteosarcoma (OS) cells in vitro and in vivo.

Uluçkan Ö, Bakiri L, Wagner EF.

Methods Mol Biol. 2015;1267:297-305. doi: 10.1007/978-1-4939-2297-0_14.

PMID:
25636475
11.

Thrombospondin-1 regulates bone homeostasis through effects on bone matrix integrity and nitric oxide signaling in osteoclasts.

Amend SR, Uluckan O, Hurchla M, Leib D, Novack DV, Silva M, Frazier W, Weilbaecher KN.

J Bone Miner Res. 2015 Jan;30(1):106-15. doi: 10.1002/jbmr.2308.

12.

Fos-dependent induction of Chk1 protects osteoblasts from replication stress.

Schulze J, Lopez-Contreras AJ, Uluçkan Ö, Graña-Castro O, Fernandez-Capetillo O, Wagner EF.

Cell Cycle. 2014;13(12):1980-6. doi: 10.4161/cc.28923. Epub 2014 Apr 24.

13.

The ADP receptor P2RY12 regulates osteoclast function and pathologic bone remodeling.

Su X, Floyd DH, Hughes A, Xiang J, Schneider JG, Uluckan O, Heller E, Deng H, Zou W, Craft CS, Wu K, Hirbe AC, Grabowska D, Eagleton MC, Townsley S, Collins L, Piwnica-Worms D, Steinberg TH, Novack DV, Conley PB, Hurchla MA, Rogers M, Weilbaecher KN.

J Clin Invest. 2012 Oct;122(10):3579-92. doi: 10.1172/JCI38576. Epub 2012 Sep 17.

14.

Dissection of platelet and myeloid cell defects by conditional targeting of the beta3-integrin subunit.

Morgan EA, Schneider JG, Baroni TE, Uluçkan O, Heller E, Hurchla MA, Deng H, Floyd D, Berdy A, Prior JL, Piwnica-Worms D, Teitelbaum SL, Ross FP, Weilbaecher KN.

FASEB J. 2010 Apr;24(4):1117-27. doi: 10.1096/fj.09-138420. Epub 2009 Nov 20.

15.

CD47 regulates bone mass and tumor metastasis to bone.

Uluçkan O, Becker SN, Deng H, Zou W, Prior JL, Piwnica-Worms D, Frazier WA, Weilbaecher KN.

Cancer Res. 2009 Apr 1;69(7):3196-204. doi: 10.1158/0008-5472.CAN-08-3358. Epub 2009 Mar 10.

16.

Interferon-gamma targets cancer cells and osteoclasts to prevent tumor-associated bone loss and bone metastases.

Xu Z, Hurchla MA, Deng H, Uluçkan O, Bu F, Berdy A, Eagleton MC, Heller EA, Floyd DH, Dirksen WP, Shu S, Tanaka Y, Fernandez SA, Rosol TJ, Weilbaecher KN.

J Biol Chem. 2009 Feb 13;284(7):4658-66. doi: 10.1074/jbc.M804812200. Epub 2008 Dec 5.

17.

APT102, a novel adpase, cooperates with aspirin to disrupt bone metastasis in mice.

Uluçkan O, Eagleton MC, Floyd DH, Morgan EA, Hirbe AC, Kramer M, Dowland N, Prior JL, Piwnica-Worms D, Jeong SS, Chen R, Weilbaecher K.

J Cell Biochem. 2008 Jul 1;104(4):1311-23. doi: 10.1002/jcb.21709.

18.

Disruption of CXCR4 enhances osteoclastogenesis and tumor growth in bone.

Hirbe AC, Rubin J, Uluçkan O, Morgan EA, Eagleton MC, Prior JL, Piwnica-Worms D, Weilbaecher KN.

Proc Natl Acad Sci U S A. 2007 Aug 28;104(35):14062-7. Epub 2007 Aug 22.

19.

Granulocyte colony-stimulating factor enhances bone tumor growth in mice in an osteoclast-dependent manner.

Hirbe AC, Uluçkan O, Morgan EA, Eagleton MC, Prior JL, Piwnica-Worms D, Trinkaus K, Apicelli A, Weilbaecher K.

Blood. 2007 Apr 15;109(8):3424-31. Epub 2006 Dec 27.

20.

Skeletal complications of breast cancer therapies.

Hirbe A, Morgan EA, Uluçkan O, Weilbaecher K.

Clin Cancer Res. 2006 Oct 15;12(20 Pt 2):6309s-6314s. Review.

Supplemental Content

Loading ...
Support Center